In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. 10513-10513
Abstract:
10513 Background: Novel agents that inhibit kinases in the hypoxia pathway [VEGF, PDGF] can achieve response rates of 30-57% in renal cell carcinoma (RCC); however, threshold levels of targets and downstream signaling proteins in patient cells have not been identified as biomarkers to guide treatment. Rapid and quantitative measurements of overall levels and % phosphorylation of proteins in the hypoxia pathway from patient specimens might better enable the development of proteomic biomarkers. Methods: We have developed the use of an automated nanoscale immuno assay (NIA) to profile hypoxia proteins in solid tumors, and now present NIA assays to measure EGFR, VEGF-R, AKT2, GSK3β, CA-9, MEK1 and ERK1/2 proteins in RCC clinical specimens. Furthermore, to decrease the amount of tissue and the invasiveness of the procedure required to obtain specimens for analysis, we have optimized assays to profile RCC specimens acquired by fine needle aspiration (FNA). Results: Unique to NIA technology, we have analyzed percent phosphorylation for phosphorylated proteins and can distinguish differences in even a single phosphorylation in the FNA specimens, allowing us to group tumors based upon different patterns of phosphorylation. In addition, we compared 10-parameter hypoxia profiles in a panel of RCC paired with adjacent non-tumor tissue and will present the proteins that can distinguish tumor from non-tumor tissue. Importantly, we have determined that we can present protein profiles to the clinical team within 8 hours of receiving the specimen (1 hour preparation time, 6 hours of unattended automated instrument time, 1 hour of analysis). Conclusions: NIA is an extremely efficient, quantitative and high-throughput platform that has the potential to be used to rapidly generate proteomic profiles for clinical specimens for the development of novel diagnostic and predictive biomarkers.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.10513
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
Permalink